BioCryst Pharmaceuticals, Inc. (BCRX) |
|
7.9925 -0.178 (-2.17%)
|
03-22 15:53 |
|
Open: |
8.16 |
Pre. Close: |
8.17 |
|
High:
|
8.24 |
Low:
|
7.975 |
|
Volume:
|
1,210,988 |
Market Cap:
|
1,506(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 3:16:12 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 10.95 One year: 12.07 |
| Support: |
Support1: 7.82 Support2: 6.5 |
| Resistance: |
Resistance1: 9.37 Resistance2: 10.34 |
| Pivot: |
8.38 |
| Moving Average: |
MA(5): 8.11 MA(20): 8.55
MA(100): 10.76 MA(250): 11.47 |
| MACD: |
MACD(12,26): -0.5  Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 23.4 %D(3): 21.4 |
| RSI: |
RSI(14): 33.1 |
| 52-week: |
High: 18 Low: 7.61 |
| Average Vol(K): |
3-Month: 3,031 (K) 10-Days: 3,089 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BCRX ] has closed above bottom band by 25.5%. Bollinger Bands are 47.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.24 - 8.29 |
8.29 - 8.34 |
|
Low:
|
7.83 - 7.89 |
7.89 - 7.95 |
|
Close:
|
8.08 - 8.17 |
8.17 - 8.25 |
|
Company Description |
|
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. |
Headline News |
Wed, 22 Mar 2023
Assenagon Asset Management S.A. Trims Stake in BioCryst ... - MarketBeat
Mon, 20 Mar 2023
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average ... - MarketBeat
Sun, 19 Mar 2023
North Star Investment Management Corp. Has $4.22 Million Position ... - MarketBeat
Fri, 10 Mar 2023
Engineers Gate Manager LP acquires new stock in BioCryst ... - Best Stocks
Wed, 08 Mar 2023
CADTH Recommends Reimbursement for BioCryst's ORLADEYO ... - Yahoo Finance
Fri, 03 Mar 2023
Bayesian Capital Management LP Makes New Investment in ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
188 (M) |
| Shares Float |
170 (M) |
|
% Held by Insiders
|
1 (%) |
|
% Held by Institutions
|
85.5 (%) |
|
Shares Short
|
29,480 (K) |
|
Shares Short P.Month
|
26,680 (K) |
Stock Financials |
|
EPS
|
-1.31 |
|
EPS Est Next Qtl
|
-0.19 |
|
EPS Est This Year
|
-0.75 |
|
EPS Est Next Year
|
-0.78 |
|
Book Value (p.s.)
|
-1.58 |
|
Profit Margin (%)
|
-91.3 |
|
Operating Margin (%)
|
-54.9 |
|
Return on Assets (ttm)
|
-16.3 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
68.6 |
|
Gross Profit (p.s.)
|
0.05 |
|
Sales Per Share
|
1.43 |
|
EBITDA (p.s.)
|
-0.79 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-162 (M) |
|
Levered Free Cash Flow
|
-142 (M) |
Stock Valuations |
|
PE Ratio
|
-6.2 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
-5.17 |
|
Price to Sales
|
5.64 |
|
Price to Cash Flow
|
-9.45 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
